HBV undetectable equals untransmissible study
Part of Digestive system, Infections clinical trials.
This study checks if having undetectable hepatitis B virus (HBV) means you cannot pass it to others. It tests this idea in people with chronic HBV who are on treatment, those not on treatment, and healthy controls.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old
- You have chronic hepatitis B infection
- If you are on treatment, you have been taking tenofovir alafenamide (TAF) or tenofovir disoproxil fumarate (TDF) for at least 2 years with undetectable virus
- If you are not on treatment, you have high or low viral load
- You have never had surgery on your urinary or reproductive tract
- You do not have HIV, hepatitis C, or hepatitis delta
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies what happens to people with hepatitis B who have hepatitis B surface antigen for more than 6 months, are “HBeAg-negative,” and have certain blood and liver-scarring levels despite normal or near-normal liver inflammation. It may help doctors understand the best care for this specific group before clear treatment phases.
This study is testing a newer, more precise way of measuring the amount of hepatitis B virus in your blood (called digital PCR) to see if it matches current testing methods. If you are a chronic hepatitis B patient, this could help make future virus monitoring more accurate.
This trial is for people with chronic hepatitis B who have already cleared the virus with interferon treatment. It tests ongoing strategies to help maintain their health and prevent the virus from coming back.
This study collects a small sample of liver cells to understand how hepatitis B virus behaves in the liver and how the immune system responds. This could help improve future treatments for chronic hepatitis B.
This Phase 2 trial studies an injection (HRS-5635), either alone or with other medicines, to see if it is safe and helps keep chronic hepatitis B under control. It is for people who are already on standard hepatitis B antivirals and have low or undetectable viral levels.
This trial tests a new drug called GST-HG141 for people with chronic hepatitis B whose virus is still active despite taking standard antiviral pills. It aims to see if the new drug can better control the virus.
Hear when a new Chronic Hepatitis B trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.